Investornewsbreaks Nrx Pharmaceuticals, Inc. (NASDAQ: NRXP) To Join H.C. Wainwright's 27Th Annual Global Investment Conference CEO Fireside Chat Set For Sept. 8, 2025, 4:30 To 5 P.M. ET
To view the full press release, visit
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc. (), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has recently filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner's National Priority Voucher Program for the treatment of suicidal depression.
NOTE TO INVESTORS: The latest news and updates relating to NRXP are available in the company's newsroom at
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers : (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ; (2) article and editorial syndication to 5,000+ outlets ; (3) enhanced press release enhancement to ensure maximum impact ; (4) social media distribution via IBN to millions of social media followers ; and (5) a full array of tailored corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: /Disclaimer
InvestorWire
Austin, Texas
512.354.7000 Office
[email protected]
InvestorWire is powered by IBN
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research

- Daytrading Publishes New Study On The Dangers Of AI Tools Used By Traders
- Primexbt Launches Empowering Traders To Succeed Campaign, Leading A New Era Of Trading
- Wallpaper Market Size, Industry Overview, Latest Insights And Forecast 2025-2033
- Excellion Finance Scales Market-Neutral Defi Strategies With Fordefi's MPC Wallet
- ROVR Releases Open Dataset To Power The Future Of Spatial AI, Robotics, And Autonomous Systems
- Ethereum-Based Meme Project Pepeto ($PEPETO) Surges Past $6.5M In Presale
Comments
No comment